Psychiatry 18 , 12941301 (2013)
Provincial/Regional Health Authorities and Hospitals Send out a provincial, regional, or hospital alert to all staff, including anesthesia teams, about the increased risk of aspiration for patients who are taking GLP-1 receptor agonists, especially when used for weight loss
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Given where the regulatory landscape stands as of May 2026, it deserves direct treatment - because it affects every compounded GLP-1 platform currently operating, and the timeline for resolution is not yet settled
Terms of Use billing breakdown, and what the 2026 FDA compounding enforcement wave means for prospective patients evaluating telehealth platforms Disclaimer: This article is for informational purposes only and is not medical advice
Not every patient needs the maximum dose